Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

 

 

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

NY-Based NorthOne, A Digital Challenger Bank For Small Businesses, Raises $21M Series A

  NorthOne, a digital challenger bank focused on small businesses, announced this morning a $21 million Series A raise. Boston-based Battery Ventures led the round, which included participation...

All Blacks great Carter retires from professional rugbyon February 20, 2021 at 8:39 am

New Zealand's Dan Carter, who won two World Cups and is world rugby's record points scorer, announces his retirement from professional rugby.The fly-half, 38,...

Egypt mummies to pass through Cairo in ancient rulers’ paradeon April 3, 2021 at 2:29 am

The Cairo spectacle will see the remains of 18 kings and four queens taken to a new resting place.The Cairo spectacle will see the...

Covid: Liverpool to stage sold out Blossoms gig as trial for festival seasonon May 2, 2021 at 8:33 am

Blossoms will play to 5,000 people to help gather research for this summer's festival season.Blossoms will play to 5,000 people to help gather research...

The Oprah Winfrey Channel Will Be There For the Young Women of Today

Do you think Oprah Winfrey will be on her way out of the channel? If so, what would happen to her? We are all...
Home of Science
Follow me